Clinical proteomics reveals vulnerabilities in non-invasive breast ductal carcinoma and drives personalized treatment strategies.
G. Mitsa, L. Florianova, J. Lafleur…·G. Batist
The paper uses clinical proteomics to identify biomarkers and metabolic vulnerabilities in DCIS, informing therapeutic strategies and developing a targeted proteomics assay for cancer-related pathways.